Andreas Hüttmann

Also affiliated with West German Heart and Vascular Center Essen, University of Duisburg-Essen

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 6 papers. Top paper: “Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients”.

Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients

Blood Advances(2021)10.1182/bloodadvances.2021004467

N/A

0.659DataRank · unranked

80 citations

C. N. Burggraaff, M. W. Heymans, U. Dührsen, Andreas Hüttmann, C. Schmitz +20 more

Integrating genetic subtypes with PET scan monitoring to predict outcome in diffuse large B-cell lymphoma

Nature Communications(2025)10.1038/s41467-024-55614-y

N/A

0.457DataRank · unranked

7 citations

Jurriaan Janssen, G. Tjitske Los-de Vries, Erik van Dijk, Julia Richter, Marcel Nijland +20 more

Positron Emission Tomography–Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial

Journal of Clinical Oncology(2025)10.1200/jco-25-00439

N/A

0.406DataRank · unranked

14 citations

Helen Kaul, Alexander Fosså, Andreas Hüttmann, Felix Keil, Yon-Dschun Ko +30 more

Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

Blood Cancer Journal(2025)10.1038/s41408-025-01329-2

N/A

0.282DataRank · unranked

5 citations

Barbara Pro, Tim Illidge, Steven M. Horwitz, Lorenz Truemper, Swaminathan P. Iyer +22 more

The Impact of Genetic Subtypes of Diffuse Large B-Cell Lymphoma for Outcome Prediction and Interpretation of FDG-PET treatment Response Monitoring

Research Square(2023)10.21203/rs.3.rs-3480882/v1

N/A

0DataRank · unranked

0 citations

Matías Mendeville, Jurriaan Janssen, G. Tjitske Los-de Vries, Erik van Dijk, Julia Richter +20 more

477 | LONGITUDINAL MULTI‐OMICS INVESTIGATION IN IBRUTINIB‐BORTEZOMIB‐R‐CHOP‐TREATED DLBCL PATIENTS

Hematological Oncology(2025)10.1002/hon.70096_477

N/A

0DataRank · unranked

0 citations

Aitomi Bittner, Mareike Frick, J. Kase, J. Hoffmann, Corinna Trenker +24 more